Earnings ·
Keros Therapeutics reports Q3 net income of $14.2M on $40M Takeda license revenue
KROSKeros Therapeutics, Inc.
Keros Therapeutics reported a net income of $14.2 million for the third quarter ended September 30, 2026, compared to a net loss of $7.3 million in the prior-year period. The turnaround was driven by $40 million in license revenue recognized from its agreement with Takeda. Operating expenses totaled $27.2 million, including $20.5 million in research and development costs and $6.7 million in general and administrative expenses. Cash and cash equivalents stood at $259.5 million as of September 30, 2026, providing a runway into the second half of 2028. The company also announced the first patient dosing in its Phase 2 trial for rinvatercept in Duchenne muscular dystrophy and nominated KER-206 from its nonclinical pipeline. Keros Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapeutics for disorders linked to dysfunctional TGF-beta signaling.